Adaptive NK cell responses in HIV/SIV infections: A roadmap to cell-based therapeutics?

Area of Science:

• Immunology
• Virology
• Cell Therapy

Background:

• Natural killer (NK) cells are crucial for antiviral and antitumor immunity.
• Current NK cell immunotherapies, primarily developed for cancer, have potential applications against HIV/SIV-infected cells.
• Chronic HIV/SIV infections create an immunosuppressive and inflammatory environment that hinders NK cell responses.

Purpose of the Study:

• To explore the application of NK cell-based immunotherapies for targeting HIV/SIV-infected cells.
• To highlight recent advancements in NK cell therapy, including CAR NK cells and IL-15 superagonists, for infectious diseases.
• To discuss the potential for generating virus-specific memory NK cells for enhanced viral control.

Main Methods:

• Review of recent research on chimeric antigen receptor (CAR) NK cells and their efficacy and safety compared to CAR T cells.
• Investigation of the role of IL-15 superagonist N803 in enhancing NK cell function in the context of chronic viral infections.
• Exploration of strategies for developing adaptive and memory NK cell responses against viral pathogens.

Main Results:

• CAR NK cells demonstrate targeted responses with potentially fewer side effects than CAR T cells.
• Inducible pluripotent stem cell-derived or cell line-derived CAR NK cells offer potential for "off-the-shelf" accessibility.
• The IL-15 superagonist N803 may enhance NK cell responses in the immunosuppressive environment of chronic HIV/SIV infections, aiding viremia control.

Conclusions:

• NK cell-based therapies, including CAR NK cells and cytokine enhancement, represent a promising strategy for combating HIV/SIV.
• The development of virus-specific memory NK cells could lead to more effective and durable immune responses against viral infections.
• NK cell-tuned immunotherapies may usher in a new era of treatment for viral diseases.